Disease Modulation Versus Modification: A Call for Revised Outcome Metrics in the Treatment of Thyroid Eye Disease.
Journal
Ophthalmic plastic and reconstructive surgery
ISSN: 1537-2677
Titre abrégé: Ophthalmic Plast Reconstr Surg
Pays: United States
ID NLM: 8508431
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
medline:
29
1
2024
pubmed:
29
1
2024
entrez:
29
1
2024
Statut:
aheadofprint
Résumé
This perspective introduces the concepts of disease-modulating and -modifying therapy for thyroid eye disease and offers novel metrics for therapeutic outcomes. A focused literature review was performed. Modulators are treatments that suppress disease symptoms whereas modifiers alter the natural history of a disease. Though many drugs are capable of exhibiting both effects, consideration of a drug's primary effect is useful when considering therapeutic options. For thyroid eye disease, corticosteroids and teprotumumab are effective at modulating many signs and symptoms of the disease, particularly those related to soft tissue inflammation. Orbital radiotherapy and rituximab have demonstrated effectiveness at durably modifying the natural history of thyroid eye disease. Outcome metrics should reflect the unique therapeutic objectives associated with disease modulation and modification. This conceptual framework should guide treatment of thyroid eye disease.
Identifiants
pubmed: 38285956
doi: 10.1097/IOP.0000000000002591
pii: 00002341-990000000-00330
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.
Déclaration de conflit d'intérêts
The authors have no financial or conflicts of interest to disclose.
Références
Gumpel JM. Cyclophosphamide, gold and penicillamine--disease-modifying drugs in rheumatoid arthritis--tailored dosage and ultimate success. Rheumatol Rehabil 1976;15:217–220.
Buer JK. A history of the term “DMARD”. Inflammopharmacology 2015;23:163–171.
Pakdel F, Haghighi A, Pirmarzdashti N. Disease modifying drugs in idiopathic sclerosing orbital inflammatory syndrome. Orbit 2021;41:437–446.
Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317–328.
Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatol 2021;73:1366–1383.
Puéchal X, Iudici M, Perrodeau E, et al.; French Vasculitis Study Group. Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with polyangiitis. JAMA Netw Open 2022;5:e2243799.
Berger JR, Malik V, Lacey S, et al. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol 2018;24:323–331.
Rundle FF, Wilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci 1945;5:177–194.
Rundle FF. Management of exophthalmos and related ocular changes in Graves’ disease. Metabolism 1957;6:36–48.
Bartley GB. Rundle and his curve. Arch Ophthalmol 2011;129:356–358.
Naik VM, Naik MN, Goldberg RA, et al. Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol 2010;55:215–226.
Patel P, Khandji J, Kazim M. Recurrent thyroid eye disease. Ophthalmic Plast Reconstr Surg 2015;31:445–448.
Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med 2016;375:1552–1565.
Yang M, Wiersinga WM, Soeters MR, et al. What is the aim of immunosuppressive treatment in patients with Graves’ orbitopathy? Ophthalmic Plast Reconstr Surg 2014;30:157–161.
Shams PN, Ma R, Pickles T, et al. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 2014;157:1299–1305.
Gold KG, Scofield S, Isaacson SR, et al. Orbital radiotherapy combined with corticosteroid treatment for thyroid eye disease-compressive optic neuropathy. Ophthalmic Plast Reconstr Surg 2018;34:172–177.
Zang S, Kahaly GJ. Steroids and the immune response in Graves orbitopathy. Immunol Endocr Metab Agents Med Chem 2011;11:90–98.
Brown J, Coburn JW, Wigod RA, et al. Adrenal steroid therapy of severe infiltrative ophthalmopathy of Graves’ disease. Am J Med 1963;34:786–795.
Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 2005;90:5234–5240.
Aktaran S, Akarsu E, Erbaǧci I, et al. Comparison of intravenous methylprednisolone therapy vs oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract 2007;61:45–51.
Bartalena L, Krassas GE, Wiersinga W, et al.; European Group on Graves' Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab 2012;97:4454–4463.
Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 2020;382:341–352.
Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 2017;376:1748–1761.
Winn BJ, Kersten RC. Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies. Ophthalmology 2021;128:1627–1651.
Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology 2022;129:438–449.
Belinsky I, Creighton FX, Mahoney N, et al. Teprotumumab and hearing loss: case series and proposal for audiologic monitoring. Ophthalmic Plast Reconstr Surg 2022;38:73–78.
Trott KR, Kamprad F. Radiobiological mechanisms of anti-inflammatory radiotherapy. Radiother Oncol 1999;51:197–203.
Kazim M, Garrity JA. Orbital radiation therapy for thyroid eye disease. J Neuro-Ophthalmol 2012;32:172–176.
Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab 1973;37:276–285.
Kazim M, Trokel S, Moore S. Treatment of acute Graves orbitopathy. Ophthalmology 1991;98:1443–1448.
Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy. J Clin Endocrinol Metab 2004;89:15–20.
Mourits MP, van Kempen-Harteveld ML, García García MB, et al. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet 2000;355:1505–1509.
Khanna D, Chong KKL, Afifiyan NF. Rituximab treatment of patients with thyroid-associated ophthalmopathy. OPHTHA 2009;117:133–139.e2.
Silkiss RZ, Reier A, Coleman M, et al. Rituximab for thyroid eye disease. Ophthalmic Plast Reconstr Surg 2010;26:310–314.
Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves ’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015;100:422–431.
Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab 2015;100:432–441.
Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 1989;73:639–644.
Dolman PJ, Rootman J. VISA classification for Graves orbitopathy. Ophthalmic Plast Reconstr Surg 2006;22:319–324.
Terwee CB, Gerding MN, Dekker FW, et al. Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998;82:773–779.
Fayers T, Dolman PJ. Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol 2011;95:1670–1674.